Formycon successfully places an EUR 70 million senior unsecured floating rate bond

Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014

NOT FOR DISTRIBUTION, PUBLICATION OR TRANSMISSION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR PUBLICATION MAY BE UNLAWFUL. FURTHER RESTRICTIONS APPLY. PLEASE REFER TO THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

Planegg-Martinsried, Germany, June 27, 2025. The management board of Formycon AG (ISIN: DE000A1EWVY8) (“Company“) today successfully placed a senior unsecured floating rate bond in a total volume of EUR 70 million (ISIN: NO0013586024 / WKN: A4DFJH) (“Bond“). The Bond has a maturity of four years and bears interest at a rate equal to EURIBOR (three months) plus a margin of 7.0% p.a.

Due to very strong demand, the offering period for the public offering of the bond has been shortened. On the back of an oversubscribed book, the volume has been increased from initially EUR 50 million to a total of EUR 70 million.

The Bond was placed with both private investors and institutional investors in Germany and abroad. All subscription orders submitted during the public offering via the subscription functionality of Deutsche Börse (DirectPlace) and the Company’s website were fully allocated up to a volume of EUR 2,000 per order and 40% for orders above, rounded to whole bonds, with each order being allocated a maximum of EUR 20,000.

The issue and value date of the Bond is July 9, 2025 (“Issue Date“). Trading of the Bond on the Regulated Unofficial Market (Freiverkehr) of the Frankfurt Stock Exchange is scheduled to commence on June 30, 2025 (trading per appearance). The Company will also apply for the inclusion of the Bond in trading on the Euronext ABM, a self-regulated marketplace organised and operated by the Oslo Stock Exchange (Oslo Børs), within six (6) months after the Issue Date.

The net proceeds received by the Company will be used to finance the development and expansion of the Company’s biosimilar product portfolio as part of its corporate growth strategy.

The transaction was advised by IKB Deutsche Industriebank AG and Pareto Securities AS as Joint Lead Managers.

For further information, please contact:

Sabrina Müller
Director Investor Relations and
Corporate Communications
T + 49 89 86 46 67 149
F + 49 89 86 46 67 110
sabrina.mueller@formycon.com

Formycon AG
Fraunhoferstraße 15
82152 Planegg/Martinsried
Germany
www.formycon.com

Important Notice

This publication may not be published, distributed or transmitted in the United States of America, Canada, Australia or Japan. It does not constitute an offer or solicitation of an offer to purchase or subscribe for any securities in the United States, Australia, Canada or Japan or in any jurisdiction in which such offer or solicitation would be unlawful.

This publication constitutes neither an offer to sell nor a solicitation to buy securities of the Company. A public offer of securities in Germany, Luxembourg and Austria is made solely based on the securities prospectus to be approved by the Commission de Surveillance du Secteur Financier (“CSSF”) and to be notified to the German Federal Financial Supervisory Authority (BaFin) and the Austrian Financial Market Authority (FMA). The approval of the securities prospectus by the CSSF should not be understood as an endorsement of the securities offered. The securities prospectus alone includes the information for investors required by law. The securities prospectus will be made available free of charge on the Company’s website (https://www.formycon.com/investoren/anleihe-2025) in the “Investor Relations” section.

Investors are recommended to read the securities prospectus carefully before deciding to purchase or sell notes of the Company in order to fully understand the potential risks and rewards associated with the decision to invest in the securities and to make an investment decision only on the basis of all available information about the Company after consultation with their own lawyers, tax and/or financial advisors.

In the Member States of the European Economic Area other than Germany, Luxembourg and Austria, this publication is only addressed to persons who are “qualified investors” within the meaning of Article 2(e) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market (“Prospectus Regulation“).

In the United Kingdom, this publication may only be distributed to, and is only directed at, persons who are “qualified investors” within the meaning of Article 2(e) of the Prospectus Regulation as that Regulation forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 and who are also (i) professional investors within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (“Order“), or (ii) are high net worth companies falling within Article 49(2)(a) to (d) of the Order or other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as “relevant persons”). The new securities will only be available to relevant persons and any invitation, offer or agreement to subscribe, purchase or otherwise acquire securities will only be made to relevant persons. Any person who is not a relevant person must not act or rely on these materials or their contents.

This publication does not constitute an offer of securities for sale in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act“). The securities may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act. There will be no public offering of these securities in the United States.

Certain statements contained in this publication may constitute “forward-looking statements”. These forward-looking statements are based on management’s current views, expectations, assumptions and information. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties.

Due to various factors, actual future results, developments and events may differ materially from those described in these statements; neither the Company nor any other person assumes any responsibility for the accuracy of the opinions contained in this communication or the underlying assumptions. The Company assumes no obligation to update any forward-looking statements contained in this publication. In addition, it should be noted that all forward-looking statements speak only as of the date hereof and that neither the Company nor the Joint Lead Managers undertake any obligation to update any forward-looking statements or to conform them to actual events or developments, except as required by law.

THIS DOCUMENT IS NOT A PROSPECTUS BUT A PROMOTIONAL DOCUMENT; INVESTORS SHOULD SUBSCRIBE FOR OR PURCHASE THE SECURITIES REFERRED TO IN THIS PROMOTIONAL DOCUMENT SOLELY ON THE BASIS OF THE INFORMATION CONTAINED IN THE PROSPECTUS.